Spyre Therapeutics, Inc. Common Stock (SYRE) Stock Price

SYREStock

$79.90+259.26%52W

Market Cap$7.47B

P/E—

PEG Ratio—

Div yield—

Beta3.20

SYRE Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)14.92%

Price vs S&P 500 (4W)-11.86%

VGM Score71.29

Book Value / Share (Quarterly)$12.50

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-2.37

Price vs S&P 500 (YTD)131.97%

Net Profit Margin (TTM)-22158.54%

EPS (TTM)$-2.32

10-Day Avg Trading Volume1.74M

EPS Excl Extra (TTM)$-2.32

EPS (Annual)$-2.42

ROI (Annual)-21.70%

Net Profit Margin (5Y Avg)-8769.93%

Cash / Share (Quarterly)$13.01

ROA (Last FY)-19.95%

EBITD / Share (TTM)$-2.69

ROE (5Y Avg)-86.62%

Operating Margin (TTM)-17559.35%

Cash Flow / Share (Annual)$-2.16

P/B Ratio6.70x

P/B Ratio (Quarterly)7.00x

Net Income / Employee (Annual)$-1,521,600

Net Interest Coverage (TTM)-6.19x

ROA (TTM)-22.23%

EPS Incl Extra (Annual)$-2.42

Current Ratio (Annual)13.25x

Quick Ratio (Quarterly)18.09x

3-Month Avg Trading Volume1.36M

52-Week Price Return259.26%

Revenue / Employee (TTM)$0

P/S Ratio (Annual)8322.89x

Asset Turnover (Annual)0.00x

52-Week High$110.17

Operating Margin (5Y Avg)-6607.37%

EPS Excl Extra (Annual)$-2.42

26-Week Price Return24.82%

Quick Ratio (Annual)12.89x

13-Week Price Return-20.28%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)18.53x

Enterprise Value$7.21B

Asset Turnover (TTM)0.01x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-38241.08%

Cash / Share (Annual)$9.68

3-Month Return Std Dev58.38%

Net Income / Employee (TTM)$-1,754,100

ROE (Last FY)-21.70%

Net Interest Coverage (Annual)-2.14x

EPS Basic Excl Extra (Annual)$-2.42

Receivables Turnover (TTM)2.51x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.32

Receivables Turnover (Annual)2.51x

ROI (TTM)-24.32%

P/S Ratio (TTM)5995.19x

Pretax Margin (5Y Avg)-8771.48%

Revenue / Share (Annual)$0.00

Price vs S&P 500 (52W)243.73%

Year-to-Date Return143.90%

5-Day Price Return-6.98%

EPS Normalized (Annual)$-2.42

ROA (5Y Avg)-66.20%

Net Profit Margin (Annual)-38238.15%

Month-to-Date Return-10.26%

EBITD / Share (Annual)$-3.27

Operating Margin (Annual)-27347.97%

ROI (5Y Avg)-86.54%

EPS Basic Excl Extra (TTM)$-2.32

P/B Ratio (Annual)3.55x

Pretax Margin (TTM)-22174.80%

Book Value / Share (Annual)$9.15

Price vs S&P 500 (13W)-22.97%

Beta3.20x

Revenue / Share (TTM)$0.00

ROE (TTM)-24.32%

52-Week Low$21.14

mGradeB

vgmGradeB

SYRE Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 4, 2026	-$0.75	-$0.36	+51.78%(+$0.39)
Q1 2026	May 5, 2026	-$0.65	-$0.74	-13.11%(-$0.09)
Q4 2025	Feb 19, 2026	-$0.80	-$0.74	+7.22%(+$0.06)
Q3 2025	Nov 4, 2025	-$0.74	-$0.15	+79.74%(+$0.59)
Q2 2025	Aug 5, 2025	-$0.71	-$0.49	+31.09%(+$0.22)

SYRE Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.48

4.39

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78
MIRMMirum Pharmaceuticals, Inc. Common Stock	F	B	C	8.4x	44.0%	81.7%	—	$80.14

About Spyre Therapeutics, Inc. Common Stock

Spyre Therapeutics is a clinical-stage biotechnology company developing long-acting antibodies for inflammatory bowel disease and rheumatic diseases. The company's pipeline features extended half-life antibodies targeting α4β7, TL1A, and IL-23, evaluated as monotherapies and pair-wise combinations to improve treatment outcomes and reduce dosing frequency.

SYRE Next Earnings Report

Report dateNov 3, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.82

Revenue estimate$0

Also reporting on Nov 3, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

SYRE Insider Transactions

SellSep 2, 2026
KING-JONES HEIDY
Officer
Shares: 28,399Value: $2.48M
SellSep 2, 2026
BURROWS SCOTT L.
Chief Financial Officer
Shares: 25,732Value: $2.28M
SellSep 1, 2026
TURTLE CAMERON
Chief Executive Officer
Shares: 15,000Value: $1.31M
SellAug 7, 2026
ALBERS JEFFREY W
Director
Shares: 23,000Value: $2.40M
SellAug 3, 2026
TURTLE CAMERON
Chief Executive Officer
Shares: 15,000Value: $1.43M

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

KYMRKymera Therapeutics, Inc. Common StockBiological Products
ESIElement Solutions Inc.Industrial Chemicals
WLKWestlake CorporationIndustrial Chemicals
NEUNewMarket CorporationIndustrial Chemicals
AXTAAxalta Coating Systems Ltd.Paints & Coatings
EMNEastman Chemical CompanyPlastics & Resins
HXLHexcel CorporationPlastics & Resins
ELFe.l.f. Beauty, Inc.Cosmetics & Toiletries

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.4

Strong Buy

Consensus rating

52-Week Range

Low$21.14

High$110.17